```
=> d his ful

     (FILE 'HOME' ENTERED AT 09:48:36 ON 12 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 09:49:05 ON 12 SEP 2005
L1             STR
L2           6 SEA SSS SAM L1
               D SCA
               D QUE
L3         250 SEA SSS FUL L1

     FILE 'HCAPLUS' ENTERED AT 10:11:44 ON 12 SEP 2005
L4           5 SEA ABB=ON  PLU=ON  L3

     FILE 'BEILSTEIN' ENTERED AT 10:14:21 ON 12 SEP 2005
L5           0 SEA SSS FUL L1

     FILE 'MARPAT' ENTERED AT 10:16:07 ON 12 SEP 2005
L6           0 SEA SSS SAM L1
L7           9 SEA SSS FUL L1
L8           8 SEA ABB=ON  PLU=ON  L7 NOT L4


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    9 SEP 2005  HIGHEST RN 862877-54-1
     DICTIONARY FILE UPDATES:   9 SEP 2005  HIGHEST RN 862877-54-1

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************ *
     *                                                            *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,  *
     * effective March 20, 2005.  A new display format, IDERL, is now   *
     * available and contains the CA role and document type information. *
     *                                                            *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
```

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 11 Sep 2005 (20050911/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN
FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005

FILE COVERS 1771 TO 2005.
FILE CONTAINS 9,271,550 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW

* **PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.**
* **NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

FILE MARPAT
FILE CONTENT: 1988-PRESENT (VOL 143 ISS 10)(20050911/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6906245 14 JUN 2005

DE 10354060 22 JUN 2005
EP 1544195 15 JUN 2005
JP 2005150306 09 JUN 2005
WO 2005060749 07 JUL 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> fil hcap
FILE 'HCAPLUS' ENTERED AT 10:21:04 ON 12 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Sep 2005 VOL 143 ISS 12
FILE LAST UPDATED: 11 Sep 2005 (20050911/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que stat l4
L1 STR



```
VAR G1=H/AK/14
VAR G2=16/17/22/24/27/31
VAR G3=H/36
VAR G4=37/HY
NODE ATTRIBUTES:
NSPEC   IS R      AT  16
NSPEC   IS RC     AT  26
NSPEC   IS RC     AT  29
NSPEC   IS RC     AT  30
NSPEC   IS RC     AT  33
NSPEC   IS RC     AT  34
NSPEC   IS RC     AT  35
NSPEC   IS RC     AT  36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  42

STEREO ATTRIBUTES: NONE
L3          250 SEA FILE=REGISTRY SSS FUL L1
L4            5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L3


=> fil beilstein
FILE 'BEILSTEIN' ENTERED AT 10:21:12 ON 12 SEP 2005
COPYRIGHT (c) 2005 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 29, 2005

FILE COVERS 1771 TO 2005.
*** FILE CONTAINS  9,271,550 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************
    NEW
* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE
```

SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> d que stat l5
L1 STR



VAR G1=H/AK/14
VAR G2=16/17/22/24/27/31
VAR G3=H/36
VAR G4=37/HY
NODE ATTRIBUTES:
NSPEC IS R AT 16
NSPEC IS RC AT 26
NSPEC IS RC AT 29
NSPEC IS RC AT 30
NSPEC IS RC AT 33
NSPEC IS RC AT 34
NSPEC IS RC AT 35
NSPEC IS RC AT 36
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L5 0 SEA FILE=BEILSTEIN SSS FUL L1

100.0% PROCESSED 50025 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.58

=> fil marpat

FILE 'MARPAT' ENTERED AT 10:21:23 ON 12 SEP 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1988-PRESENT (VOL 143 ISS 10)(20050911/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 6906245 14 JUN 2005
DE 10354060 22 JUN 2005
EP 1544195 15 JUN 2005
JP 2005150306 09 JUN 2005
WO 2005060749 07 JUL 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> d que stat l8
L1 STR



VAR G1=H/AK/14
VAR G2=16/17/22/24/27/31
VAR G3=H/36
VAR G4=37/HY
NODE ATTRIBUTES:
NSPEC IS R AT 16
NSPEC IS RC AT 26
NSPEC IS RC AT 29
NSPEC IS RC AT 30
NSPEC IS RC AT 33
NSPEC IS RC AT 34
NSPEC IS RC AT 35
NSPEC IS RC AT 36
DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE
L3 250 SEA FILE=REGISTRY SSS FUL L1
L4 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L3
L7 9 SEA FILE=MARPAT SSS FUL L1
L8 8 SEA FILE=MARPAT ABB=ON PLU=ON L7 NOT L4

=> d l4 ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:549856 HCAPLUS
TITLE: Parallel solution-phase synthesis of a 2,6,8,9-tetrasubstituted purine library via a sulfur intermediate
AUTHOR(S): Liu, Jinglin; Dang, Qun; Wei, Zhonglin; Zhang, Hengbin; Bai, Xu
CORPORATE SOURCE: Center for Combinatorial Chemistry and Drug Discovery, Jilin University, Changchun, 130012, Peop. Rep. China
SOURCE: Journal of Combinatorial Chemistry (2005), 7(4), 627-636
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Purine analogs exhibiting a wide range of pharmacol. activities have been considered a privileged structure in medicinal chemical In addition, the purine core consisting of four points of structural diversity is a well-sought scaffold in combinatorial chemical Although most of the efforts have been focused on 2,6,9-, 6,8,9-, or 2,8,9-trisubstituted purines, syntheses of 2,6,8,9-tetrasubstituted purines are rare. A parallel solution phase approach for the synthesis of fully substituted purines, e.g., I, via a 6-sulfur-substituted pyrimidine as the key intermediate is presented.

This strategy combining construction and modification of the purine ring thus increased the structural diversity of the final products. Sequential substitution of chlorines in 4,6-dichloro-2-methyl-5-nitropyrimidine with primary amine and benzylmercaptan afforded the 4-amino-6-benzylthio-5-nitropyrimidine, which was readily converted to its diaminopyrimidine analog by reduction of the nitro group. The diaminopyrimidine intermediate was cyclized to construct the purine ring with a C-8 substituent. Eventual oxidation of sulfur to sulfone and subsequent displacement by a primary or secondary amine provided the desired 2,6,8,9-tetrasubstituted purine analogs. This synthetic methodol. was validated with the synthesis of a 216-member purine library.

IT **862773-70-4P 862773-71-5P 862773-73-7P**
862773-82-8P 862773-83-9P 862773-85-1P
862773-88-4P 862773-89-5P 862773-91-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(parallel solution-phase preparation of substituted purines via amination of dichloro(methyl)nitropyrimidine with amines followed by sulfanylation with benzylthiol, reduction, cyclization with aldehydes, oxidation, and substitution with amines)

RN 862773-70-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-71-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-73-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-82-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-83-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-85-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-88-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-89-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 862773-91-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:294668 HCAPLUS
DOCUMENT NUMBER: 143:7926
TITLE: Adenosine Kinase Inhibitors. 4. 6,8-Disubstituted Purine Nucleoside Derivatives. Synthesis, Conformation, and Enzyme Inhibition
AUTHOR(S): Bookser, Brett C.; Matelich, Michael C.; Ollis,

Kristin; Ugarkar, Bheemarao G.
CORPORATE SOURCE: Metabasis Therapeutics, Inc., San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(9), 3389-3399
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 6,8-Disubstituted purine nucleosides were synthesized and evaluated as adenosine kinase inhibitors (AKIs). A method was developed to selectively substitute arylamines for halogens at C6 and C8 which utilizes alkali salts of arylamino anions. Regioselectivity was found to be counterion dependent. Potassium and sodium salts add selectively to C6 of 6-chloro-8-iodo-9-(2,3,5-tris-O-tert-butyldimethylsilyl-β-D-ribofuranosyl)purine while lithium salts add to C6 and C8 positions. Differential 6,8-bis-arylamin-N,N'-di-yl-purine nucleosides such as 8-anilin-N-yl-6-indolin-N-yl-9-(β-D-ribofuranosyl)purine (I) can be prepared by employing stepwise reactions of potassium and then lithium salts of different arylamino anions followed by fluoride ion-induced desilylation. Other C8-substituted compds. were prepared by way of either C8 lithiation chemical or palladium cross-coupling reactions. Several of these compds. were potent AKIs (e.g. I, AK IC50 = 0.019 μM) and are more potent than the previous best purine-based AKI 5'-deoxy-5'-amino-adenosine (AK IC50 = 0.170 μM). AK inhibitory potency was greatest for those compds. with 1H NMR evidence of a predominant anti glycosyl bond conformation, whereas most analogs adopt a syn conformation because of steric repulsions between the C8 substituent and the ribose group. The inhibitors are proposed to bind in the anti conformation with the hydrophobic C6 and C8 substituents contributing to AK affinity in a manner similar to the C4 and C5 aryl substituents of the potent diaryl-tubercidin nucleoside inhibitor series.

IT **852540-41-1P 852540-51-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation via regioselective substitution, cross-coupling reactions, steric effect, conformation, and structure activity of 6,8-disubstituted purine nucleosides as adenosine kinase inhibitors)

RN 852540-41-1 HCAPLUS
CN 9H-Purine, 6,8-bis(2,3-dihydro-1H-indol-1-yl)-9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 852540-51-3 HCAPLUS
CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-8-(2-furanyl)-9-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **852540-40-0P 852540-50-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation via regioselective substitution, cross-coupling reactions, steric effect, conformation, and structure activity of 6,8-disubstituted purine nucleosides as adenosine kinase inhibitors)
RN 852540-40-0 HCAPLUS
CN 9H-Purine, 6,8-bis(2,3-dihydro-1H-indol-1-yl)-9-[2,3,5-tris-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 852540-50-2 HCAPLUS
CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-8-(2-furanyl)-9-[2,3,5-tris-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:200119 HCAPLUS
DOCUMENT NUMBER: 142:430225
TITLE: Preparation of a fully substituted purine library
AUTHOR(S): Yang, Jianxin; Dang, Qun; Liu, Jinglin; Wei, Zhonglin; Wu, Jinchang; Bai, Xu
CORPORATE SOURCE: The Center for Combinatorial Chemistry and Drug

Discovery, Jilin University, Changchun, Jilin, 130012, Peop. Rep. China
SOURCE: Journal of Combinatorial Chemistry (2005), 7(3), 474-482
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A library of tetra-substituted purine analogs, e.g., I, was readily prepared via parallel synthesis. This strategy relied on a key cyclization of a 4,5-diaminopyrimidine with either a carboxylic acid or its derivative to construct the 2,8,9-trisubstituted 6-chloropurine core. Further elaborations of this core allowed the introduction of other diversity points. This methodol. was demonstrated through the preparation of a 135-membered library of tetra-substituted purines in good yields and high purity.

IT **850871-39-5P 850871-41-9P 850871-45-3P 850871-47-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of purines via amination of amino(dichloro)pyrimidines with amines followed by heterocyclization with carbonyl derivs. and substitution with amines)

RN 850871-39-5 HCAPLUS
CN 9H-Purine, 8,9-bis(4-fluorophenyl)-2-methyl-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 850871-41-9 HCAPLUS

CN 9H-Purine, 8,9-bis(4-fluorophenyl)-2-methyl-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 850871-45-3 HCAPLUS
CN 9H-Purine, 9-(4-fluorophenyl)-2-methyl-6-(4-morpholinyl)-8-phenyl- (9CI) (CA INDEX NAME)



RN 850871-47-5 HCAPLUS
CN 9H-Purine, 9-(4-fluorophenyl)-2-methyl-8-phenyl-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:160837 HCAPLUS
DOCUMENT NUMBER: 142:233372
TITLE: Pharmaceutical composition using a combination of an

opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

INVENTOR(S): Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043327	A1	20050224	US 2004-870209	20040617
WO 2005018645	A1	20050303	WO 2004-IB2596	20040809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-496803P P 20030821

AB Pharmaceutical compns. are disclosed for the treatment of alc. or cocaine dependence or addiction, tobacco dependence or addiction, reduction of alc. withdrawal symptoms or aiding in the cessation or lessening of alc. use or substance abuse or other behavioral dependencies including gambling. The pharmaceutical compns. are comprised of a therapeutically effective combination of an opioid receptor antagonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compds. is also disclosed.

IT **686344-19-4 686344-21-8 686344-22-9**
686344-23-0 686344-24-1 686344-25-2
686344-26-3 686344-27-4 686344-28-5
686344-29-6 686344-30-9 686344-31-0
686344-33-2 686344-35-4 686344-36-5
686344-37-6 686344-38-7 686344-39-8
686344-40-1 686344-41-2 686344-42-3
686344-43-4 686344-44-5 686345-45-9
686347-23-9 749207-87-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

RN 686344-19-4 HCAPLUS

CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-21-8 HCAPLUS
CN 3-Azetidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686344-22-9 HCAPLUS
CN 3-Azetidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-

6-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686344-23-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 686344-24-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 686344-25-2 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)



RN 686344-26-3 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-27-4 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686344-28-5 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686344-29-6 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-30-9 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-31-0 HCAPLUS
CN 4-Piperidinecarboxamide, 4-amino-1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-33-2 HCAPLUS
CN Ethanone, 1-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 686344-35-4 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-36-5 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 686344-37-6 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-38-7 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686344-39-8 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686344-40-1 HCAPLUS
CN 4-Oxa-1,9-diazaspiro[5.5]undecan-2-one, 9-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 686344-41-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 686344-42-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-[(1-cyclohexyl-3-azetidinyl)oxy]-8-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 686344-43-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1,1-dimethylethoxy)- (9CI) (CA INDEX NAME)



RN 686344-44-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 686345-45-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-23-9 HCAPLUS
CN 2-Piperazinecarboxamide, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 749207-87-2 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl-, (1α,5α,6α)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:370934 HCAPLUS
DOCUMENT NUMBER: 140:391293
TITLE: Preparation of purines as cannabinoid receptor ligands (CB-1 receptor antagonists).
INVENTOR(S): Griffith, David Andrew
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037823	A1	20040506	WO 2003-IB4619	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004092520	A1	20040513	US 2003-689381	20031020
CA 2503900	AA	20040506	CA 2003-2503900	20031021
BR 2003014918	A	20050802	BR 2003-14918	20031021

EP 1558615 A1 20050803 EP 2003-751149 20031021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
NL 1024643 A1 20040503 NL 2003-1024643 20031028
NL 1024643 C2 20050201
PRIORITY APPLN. INFO.: US 2002-421874P P 20021028
WO 2003-IB4619 W 20031021
OTHER SOURCE(S): MARPAT 140:391293
GI



I

AB Title compds. [I; A, B = (substituted) aryl, heteroaryl; R1 = H, alkyl, haloalkyl, alkoxy; R4 = specified (substituted) alkoxy, cycloalkoxy, N-heterocyclyl, etc.], were prepared Thus, 6-chloro-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purine (preparation given) was added to a mixture prepared from Na and Me2CHOH followed by stirring at room temperature overnight to give 26% 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-isopropoxy-9H-purine. In a CB-1 receptor binding assay, I showed binding activities in the range of 0.17 nM to 1 μM.

IT **686344-18-3P 686344-19-4P 686344-20-7P**
686344-21-8P 686344-22-9P 686344-23-0P
686344-24-1P 686344-25-2P 686344-26-3P
686344-27-4P 686344-28-5P 686344-29-6P
686344-30-9P 686344-31-0P 686344-32-1P
686344-33-2P 686344-34-3P 686344-35-4P
686344-36-5P 686344-37-6P 686344-38-7P
686344-39-8P 686344-40-1P 686344-41-2P
686344-42-3P 686344-43-4P 686344-44-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of purines as cannabinoid receptor ligands (CB-1 receptor antagonists))

RN 686344-18-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(4-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-19-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(2-pyrimidinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-20-7 HCAPLUS
CN 1-Piperazinecarboxamide, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 686344-21-8 HCAPLUS
CN 3-Azetidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686344-22-9 HCAPLUS
CN 3-Azetidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686344-23-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-24-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-25-2 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)



RN 686344-26-3 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-27-4 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686344-28-5 HCAPLUS

CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686344-29-6 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-30-9 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-31-0 HCAPLUS
CN 4-Piperidinecarboxamide, 4-amino-1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-32-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)



RN 686344-33-2 HCAPLUS
CN Ethanone, 1-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 686344-34-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 686344-35-4 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-36-5 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 686344-37-6 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686344-38-7 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686344-39-8 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686344-40-1 HCAPLUS
CN 4-Oxa-1,9-diazaspiro[5.5]undecan-2-one, 9-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 686344-41-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[[1-(phenylmethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 686344-42-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-[(1-cyclohexyl-3-azetidinyl)oxy]-8-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 686344-43-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1,1-dimethylethoxy)- (9CI) (CA INDEX NAME)



RN 686344-44-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-methylethoxy)-
(9CI) (CA INDEX NAME)



IT 686344-73-0P 686344-74-1P 686344-75-2P
686344-76-3P 686344-77-4P 686344-78-5P
686344-79-6P 686344-80-9P 686344-81-0P
686344-82-1P 686344-83-2P 686344-84-3P
686344-85-4P 686344-86-5P 686344-87-6P
686344-88-7P 686344-89-8P 686344-90-1P
686344-91-2P 686344-92-3P 686344-93-4P
686344-94-5P 686344-95-6P 686344-96-7P
686344-97-8P 686344-99-0P 686345-00-6P
686345-03-9P 686345-04-0P 686345-08-4P
686345-18-6P 686345-21-1P 686345-26-6P
686345-42-6P 686345-43-7P 686345-44-8P
686345-45-9P 686345-46-0P 686345-49-3P
686345-51-7P 686345-52-8P 686345-53-9P
686345-57-3P 686345-58-4P 686345-59-5P
686345-70-0P 686345-80-2P 686345-81-3P
686345-82-4P 686345-85-7P 686345-86-8P
686345-87-9P 686345-88-0P 686345-89-1P
686345-90-4P 686345-91-5P 686345-92-6P
686345-93-7P 686345-94-8P 686345-95-9P
686345-96-0P 686345-97-1P 686345-98-2P
686345-99-3P 686346-00-9P 686346-01-0P
686346-02-1P 686346-03-2P 686346-04-3P
686346-05-4P 686346-07-6P 686346-08-7P
686346-09-8P 686346-10-1P 686346-11-2P
686346-13-4P 686346-14-5P 686346-15-6P
686346-17-8P 686346-18-9P 686346-19-0P
686346-20-3P 686346-21-4P 686346-22-5P

686346-23-6P 686346-24-7P 686346-25-8P
686346-26-9P 686346-27-0P 686346-28-1P
686346-31-6P 686346-32-7P 686346-33-8P
686346-35-0P 686346-36-1P 686346-37-2P
686346-38-3P 686346-39-4P 686346-40-7P
686346-43-0P 686346-46-3P 686346-59-8P
686346-61-2P 686346-62-3P 686346-63-4P
686346-64-5P 686346-65-6P 686346-66-7P
686346-67-8P 686346-68-9P 686346-69-0P
686346-70-3P 686346-71-4P 686346-72-5P
686346-73-6P 686346-74-7P 686346-75-8P
686346-76-9P 686346-77-0P 686346-78-1P
686346-79-2P 686346-80-5P 686346-81-6P
686346-82-7P 686346-83-8P 686346-84-9P
686346-85-0P 686346-86-1P 686346-87-2P
686346-88-3P 686346-89-4P 686346-90-7P
686346-91-8P 686346-92-9P 686346-93-0P
686346-94-1P 686346-95-2P 686346-96-3P
686346-97-4P 686346-98-5P 686346-99-6P
686347-00-2P 686347-01-3P 686347-02-4P
686347-03-5P 686347-04-6P 686347-05-7P
686347-06-8P 686347-07-9P 686347-08-0P
686347-09-1P 686347-11-5P 686347-12-6P
686347-13-7P 686347-14-8P 686347-15-9P
686347-16-0P 686347-17-1P 686347-18-2P
686347-19-3P 686347-20-6P 686347-21-7P
686347-22-8P 686347-23-9P 686347-24-0P
686347-25-1P 686347-26-2P 686347-27-3P
686347-28-4P 686347-29-5P 686347-30-8P
686347-31-9P 686347-32-0P 686347-33-1P
686347-34-2P 686347-35-3P 686347-36-4P
686347-37-5P 686347-38-6P 686347-41-1P
686347-44-4P 686347-47-7P 686347-50-2P
686347-51-3P 686347-52-4P 686347-53-5P
686347-54-6P 686347-55-7P 686347-56-8P
686347-57-9P 686347-58-0P 686744-55-8P
686744-56-9P 686744-57-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of purines as cannabinoid receptor ligands (CB-1 receptor antagonists))

RN 686344-73-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-methylethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686344-74-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-methoxy- (9CI) (CA INDEX NAME)







RN 686344-75-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-ethoxy- (9CI) (CA INDEX NAME)







RN 686344-76-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-propoxy- (9CI) (CA INDEX NAME)



RN 686344-77-4 HCAPLUS
CN 9H-Purine, 6-butoxy-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 686344-78-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[[1-

(diphenylmethyl)-3-azetidinyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686344-79-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-80-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-81-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1-ethyl-3-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-82-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1-methyl-3-piperidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-83-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1-ethyl-3-pyrrolidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-84-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1-methyl-3-pyrrolidinyl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-85-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 686344-86-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]- (9CI) (CA INDEX NAME)



RN 686344-87-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 686344-88-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(tetrahydro-2-furanyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 686344-89-8 HCAPLUS
CN 2(3H)-Furanone, 3-[[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]oxy]dihydro- (9CI) (CA INDEX NAME)



RN 686344-90-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)







RN 686344-91-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1,3-dioxolan-2-ylmethoxy)- (9CI) (CA INDEX NAME)



RN 686344-92-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 686344-93-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(3,3-dimethoxypropoxy)- (9CI) (CA INDEX NAME)







RN 686344-94-5 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-ethoxy- (9CI) (CA INDEX NAME)



RN 686344-95-6 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 686344-96-7 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 686344-97-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)







RN 686344-99-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-piperidinyl)-
(9CI) (CA INDEX NAME)



RN 686345-00-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-morpholinyl)-
(9CI) (CA INDEX NAME)



RN 686345-03-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686345-04-0 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 686345-08-4 HCAPLUS
CN 2-Piperidinecarboxylic acid, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686345-18-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686345-21-1 HCAPLUS
CN 9H-Purine, 6-(1-azetidinyl)-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-(9CI) (CA INDEX NAME)



RN 686345-26-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(2,5-dimethyl-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686345-42-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-ethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686345-43-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686345-44-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 686345-45-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-46-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 686345-49-3 HCAPLUS
CN 3-Pyrrolidinamine, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 686345-51-7 HCAPLUS
CN 3-Pyrrolidinamine, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686345-52-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(4-propyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686345-53-9 HCAPLUS
CN 2-Piperidinemethanamine, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 686345-57-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686345-58-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(3,5-dimethyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686345-59-5 HCAPLUS
CN 3-Pyrrolidinamine, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686345-70-0 HCAPLUS
CN Isoquinoline, 2-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 686345-80-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[2-(2-methyl-4-pyridinyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 686345-81-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-[2-(3-pyridinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)







RN 686345-82-4 HCAPLUS
CN 1,7-Naphthyridine, 7-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 686345-85-7 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686345-86-8 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 686345-87-9 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-88-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-89-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-90-4 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-91-5 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)



RN 686345-92-6 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 686345-93-7 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(propylamino)- (9CI) (CA INDEX NAME)



RN 686345-94-8 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686345-95-9 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686345-96-0 HCAPLUS
CN 4-Piperidinone, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)



RN 686345-97-1 HCAPLUS
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 686345-98-2 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686345-99-3 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686346-00-9 HCAPLUS
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 686346-01-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-(cyclohexylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686346-02-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-4-(cyclohexylamino)- (9CI) (CA INDEX NAME)



RN 686346-03-2 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(cyclohexylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 686346-04-3 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686346-05-4 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 686346-07-6 HCAPLUS
CN 2-Piperazinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 686346-08-7 HCAPLUS
CN 3-Pyrrolidinamine, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 686346-09-8 HCAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686346-10-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl)- (9CI) (CA INDEX NAME)



RN 686346-11-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-6-(1-piperazinyl)-(9CI) (CA INDEX NAME)



RN 686346-13-4 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl-, monohydrochloride, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 686346-14-5 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686346-15-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 686346-17-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-2-(2,2-dimethylpropyl)-8-(2-fluorophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)





RN 686346-18-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-(1-methylethyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)





RN 686346-19-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-propyl-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-20-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-(1-methylethyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-21-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-2-(2,2-dimethylpropyl)-8-(2-fluorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-22-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-2-methyl-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-23-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686346-24-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 686346-25-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 686346-26-9 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 686346-27-0 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 686346-28-1 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 686346-31-6 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 686346-32-7 HCAPLUS
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)



RN 686346-33-8 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686346-35-0 HCAPLUS
CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)



RN 686346-36-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(cyclohexylamino)- (9CI) (CA INDEX NAME)



RN 686346-37-2 HCAPLUS
CN 2-Piperazinecarboxylic acid, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686346-38-3 HCAPLUS
CN 3-Azetidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 686346-39-4 HCAPLUS
CN Carbamic acid, [(1α,5α,6α)-3-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686346-40-7 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, dihydrochloride, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 686346-43-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 686346-46-3 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686346-59-8 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-61-2 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686346-62-3 HCAPLUS
CN 9H-Purine, 8-(3-chlorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-63-4 HCAPLUS
CN 9H-Purine, 8,9-bis(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-64-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-fluorophenyl)-6-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686346-65-6 HCAPLUS
CN Benzonitrile, 2-[9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-9H-purin-8-yl]- (9CI) (CA INDEX NAME)



RN 686346-66-7 HCAPLUS
CN Benzonitrile, 3-[9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-9H-purin-8-yl]- (9CI) (CA INDEX NAME)



RN 686346-67-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-fluorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-68-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-dimethoxyphenyl)-6-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 686346-69-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-8-[4-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686346-70-3 HCAPLUS
CN 9H-Purine, 8-(4-chloro-2-methoxyphenyl)-9-(4-chlorophenyl)-6-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-71-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-ethoxyphenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-72-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3,4-difluorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-73-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-methoxyphenyl)-6-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 686346-74-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-[4-(1-methylethoxy)phenyl]-6-(1-
pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-75-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-methoxyphenyl)-6-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 686346-76-9 HCAPLUS
CN 9H-Purine, 8-(3-chloro-4-fluorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-77-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-fluoro-2-methylphenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-78-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-[4-(difluoromethoxy)phenyl]-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-79-2 HCAPLUS
CN 9H-Purine, 8-(4-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-80-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-[3-(difluoromethoxy)phenyl]-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-81-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-phenyl-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-82-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,3-difluorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-83-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,4-difluorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-84-9 HCAPLUS
CN 9H-Purine, 8-(2-chloro-4-fluorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-85-0 HCAPLUS
CN 9H-Purine, 8-(3-chloro-2-fluorophenyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-86-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(5-methyl-3-furanyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686346-87-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-chloro-2-thienyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686346-88-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(4,5-dichloro-3-isothiazolyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-89-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-pyrazinyl-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686346-90-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(5-methyl-2-thienyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-91-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(5-chloro-2-thienyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686346-92-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-methyl-2-furanyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686346-93-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-8-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 686346-94-1 HCAPLUS
CN 9H-Purine, 8-(2,1,3-benzoxadiazol-5-yl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-95-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-[5-(1,1-dimethylethyl)-2-methyl-3-furanyl]-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-96-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,5-dimethyl-3-furanyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-97-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-[5-methyl-2-(trifluoromethyl)-3-furanyl]-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-98-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(3-methyl-2-thienyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686346-99-6 HCAPLUS
CN 9H-Purine, 8-(5-chloro-4-methoxy-3-thienyl)-9-(4-chlorophenyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686347-00-2 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-8-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 686347-01-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2,3-dihydro-7-benzofuranyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 686347-02-4 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-pyridinyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686347-03-5 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(6-methyl-3-pyridinyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686347-04-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-(1-pyrrolidinyl)-8-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 686347-05-7 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(4-pyridinyl)-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 686347-06-8 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-chloro-3-pyridinyl)-6-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 686347-07-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(6-chloro-3-pyridinyl)-6-(1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 686347-08-0 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-chloro-4-pyridinyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686347-09-1 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(4-methyl-3-pyridinyl)-6-(1-pyrrolidinyl)-(9CI) (CA INDEX NAME)



RN 686347-11-5 HCAPLUS
CN 4-Piperidinecarboxylic acid, 4-amino-1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 686347-12-6 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 686347-13-7 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(methylamino)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-14-8 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-15-9 HCAPLUS
CN 4-Piperidinecarbonitrile, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 686347-16-0 HCAPLUS
CN 4-Piperidinecarbonitrile, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 686347-17-1 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-18-2 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-hydroxy-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● HCl

RN 686347-19-3 HCAPLUS
CN 4-Piperidinemethanol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-20-6 HCAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 686347-21-7 HCAPLUS
CN 2-Piperazinecarboxamide, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-

6-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686347-22-8 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)-N-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-23-9 HCAPLUS
CN 2-Piperazinecarboxamide, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 686347-24-0 HCAPLUS
CN 4-Oxa-1,9-diazaspiro[5.5]undecan-2-one, 9-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 686347-25-1 HCAPLUS
CN 3-Azetidinecarboxylic acid, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 686347-26-2 HCAPLUS
CN Ethanone, 1-[1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-phenyl-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 686347-27-3 HCAPLUS
CN 4-Piperidinol, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 686347-28-4 HCAPLUS
CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]- (9CI) (CA INDEX NAME)



RN 686347-29-5 HCAPLUS
CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-5-methyl- (9CI) (CA INDEX NAME)



RN 686347-30-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 3-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-6-(4-morpholinyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686347-31-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexane-6-carboxamide, 3-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-6-(4-morpholinyl)-, (1α,5α,6α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 686347-32-0 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-9-(4-chlorophenyl)-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 686347-33-1 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-6-ethoxy-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-34-2 HCAPLUS
CN 9H-Purine, 8-(4-chlorophenyl)-6-ethoxy-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-35-3 HCAPLUS
CN 9H-Purine, 6-ethoxy-8-(2-methylphenyl)-9-[4-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 686347-36-4 HCAPLUS
CN 9H-Purine, 8-(3-chlorophenyl)-9-(4-chlorophenyl)-6-ethoxy- (9CI) (CA INDEX NAME)





RN 686347-37-5 HCAPLUS
CN 9H-Purine, 8,9-bis(4-chlorophenyl)-6-ethoxy- (9CI) (CA INDEX NAME)



RN 686347-38-6 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-ethoxy-8-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 686347-41-1 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-6-(1-methylethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-44-4 HCAPLUS
CN 9H-Purine, 8-(4-chlorophenyl)-6-(1-methylethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-47-7 HCAPLUS
CN 9H-Purine, 6-(1-methylethoxy)-8-(2-methylphenyl)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-50-2 HCAPLUS
CN 9H-Purine, 8,9-bis(4-chlorophenyl)-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 686347-51-3 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-6-(1-methylethoxy)-8-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 686347-52-4 HCAPLUS
CN 9H-Purine, 8-(2-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-53-5 HCAPLUS
CN 9H-Purine, 8-(3-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-54-6 HCAPLUS
CN 9H-Purine, 8-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-55-7 HCAPLUS
CN 9H-Purine, 8-(2-methylphenyl)-6-(2,2,2-trifluoroethoxy)-9-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 686347-56-8 HCAPLUS
CN 9H-Purine, 8-(3-chlorophenyl)-9-(4-chlorophenyl)-6-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)





RN 686347-57-9 HCAPLUS
CN 9H-Purine, 9-(4-chlorophenyl)-8-(2-methylphenyl)-6-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)



RN 686347-58-0 HCAPLUS
CN 4-Piperidinone, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, oxime (9CI) (CA INDEX NAME)



RN 686744-55-8 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-9H-purin-6-yl]-N,N-dimethyl-, monohydrochloride, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 686744-56-9 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 686744-57-0 HCAPLUS
CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[9-(4-chlorophenyl)-8-(2-fluorophenyl)-9H-purin-6-yl]-, (1α,5α,6β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **686346-06-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of purines as cannabinoid receptor ligands (CB-1 receptor antagonists))
RN 686346-06-5 HCAPLUS
CN 1,3-Piperazinedicarboxylic acid, 4-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-, 1-(1,1-dimethylethyl) 3-ethyl ester (9CI) (CA INDEX NAME)



=> d l8 ibib abs qhit 1-
YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:174185 MARPAT
TITLE: Preparation of purines and pyrrolopyrimidines as selective kinase inhibitors
PATENT ASSIGNEE(S): Merckle GmbH, Germany

SOURCE: Eur. Pat. Appl., 64 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1444982	A1	20040811	EP 2003-2753	20030206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: EP 2003-2753 20030206
GI



I

AB Title compds. [I; R1 = H, halo, alkoxy, (substituted) PhNH, PhO, PhCH2S, PhS, Ph, PhCH2, styryl, etc.; R2 = H, alkyl; X = N, NR3; Y = N, CR5, NR6; 1 dotted line = double bond, the other = single bond; R3 = H, alkyl, (substituted) Ph, PhCH2; R4 = H, halo, C.tplbond.C(CH2)mOH, (substituted) Ph; m = 1-3; R5 = H; R6 = H, (substituted) Ph, PhCH2], were prepared as selective kinase inhibitors. Thus, 6-chloro-9H-purine, PhNH2, and Et3N were refluxed 4.5 h in BuOH to give 76% N-phenyl(9H-purin-6-yl)amine. This at 30 μM gave 34% inhibition of SAPK2a kinase.

MSTR 1



G1 = OMe
G5 = 37



G7 = Ph (opt. substd. by 1 or more G4)
G10 = Ph (opt. substd. by (1-2) G11)
G13 = N
Patent location: claim 1

L8 ANSWER 2 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 140:423675 MARPAT

TITLE: A preparation of hetero-substituted benzimidazole derivatives useful as antiviral agents
INVENTOR(S): Lackey, John William
PATENT ASSIGNEE(S): Trimeris, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043913	A2	20040527	WO 2003-US35542	20031106
WO 2004043913	A3	20040923		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004166137	A1	20040826	US 2003-704224	20031106
PRIORITY APPLN. INFO.:			US 2002-424940P	20021108

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel hetero-substituted benzimidazole derivs. of formula I [wherein: Z1, Z2, Z3, Z4 are each independently N or C, and at least one of Z1, Z2, Z3, Z4 is C; R1 and R2 are each independently H, (un)saturated (un)substituted alkyl, (un)substituted (hetero)cycloalkyl, (hetero)aryl, etc.; R3 is H, halide, OH, (un)substitute aryl, arylalkyl, etc.; R4, R5, R6, R7 are each independently H, halide, alkyl, OH, alkoxy, etc.; X is a bond, (un)substituted alkyl, -alkyl-N-, -alkyl-O-, -C:N-, C(O), etc.; Y is N, P, O, S; if Y is O or S, R2 is not present], useful as antiviral agents. The invention encompasses hetero-substituted benzimidazole compds. that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of hetero-substituted benzimidazole compds. as inhibitors of membrane fusion associated events, such as viral transmission. The invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compds. of the invention. For instance, imidazopyridine derivative II [PRA(IC50) = 0.001 μg/mL; XTT(CC50) = 100 μg/mL] was prepared via heterocyclization of of the prepared benzimidazole derivative III with ClCH2C(:NH)OEt and subsequent amination of the obtained imidazopyridine IV by morpholine.

MSTR 1



G1 = 9-1 10-3



G2 = Ph
G4 = OMe
G5 = (up to 3) N / 14



G11 = Ph (opt. substd. by 1 or more G20)
Patent location: claim 1
Note: or pharmaceutically acceptable salts, prodrugs, solvates, hyrdates, and clathrates
Note: substitution is restricted
Stereochemistry: and enantiomers, diastereomers, racemates, and mixtures

L8 ANSWER 3 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 140:327061 MARPAT
TITLE: Nucleoside derivatives for treating hepatitis C virus infection
INVENTOR(S): Roberts, Christopher Don; Dyatkina, Natalia B.
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028481	A2	20040408	WO 2003-US31433	20030930

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499253 AA 20040408 CA 2003-2499253 20030930
PRIORITY APPLN. INFO.: US 2002-415222P 20020930
US 2003-443169P 20030129
WO 2003-US31433 20030930

AB Nucleoside compns. and methods for treating hepatitis C virus infections. Thus, 9-(2'-C-methyl-β-D-ribofuranosyl)-6-methoxyaminopurine was prepared by the reaction of 6-chloro-9-(2'-C-methyl-β-D-ribofuranosyl)purine and methxylamine. This compound exhibited anti-hepatitis C activity by inhibiting HCV polymerase.

MSTR 1



G5 = 349-4 343-15



G6 = 512



G10 = 553



Patent location: claim 1
Note: and pharmaceutically acceptable prodrugs and salts
Note: substitution is restricted
Note: also incorporates claim 12

L8 ANSWER 4 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:292251 MARPAT

TITLE: Preparation of imidazopyridines as kinase inhibitors
INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Garland, Stephen; Goodman, Krista B.; Haifeng, Cui; Hilfiker, Mark A.; Lee, Dennis; Panchal, Terence Aaron; Stavenger, Robert A.; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080610	A1	20031002	WO 2003-GB1205	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1490367	A1	20041229	EP 2003-744904	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005526802	T2	20050908	JP 2003-578364	20030321
US 2005197328	A1	20050908	US 2004-508760	20040922
PRIORITY APPLN. INFO.:			GB 2002-6860	20020322
			WO 2003-GB1205	20030321

GI





AB This patent concerns imidazopyridines (shown as I; variables defined

below; e.g. 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-ylamine) and physiol. acceptable salts and or N-oxides thereof, processes for their preparation, pharmaceutical compns. containing them and their use in medicine. For I, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X2, X3 and X4 = N; R1 is a 5-, or 6-membered heterocyclic group II, III, IV or V wherein X5 is a N or CR7: and X6 is a O, S or NR8; X7 and X8, which may be the same or different is a N or CR9; X9 is a O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and = N or R11; addnl. details are given in the claims. For Rho-kinase (ROCK) activity the compds. I of the examples have a pIC50 of 9 to 5.2; for mitogen and stress activated protein kinase-1 (Msk-1) activity the compds. I of the examples have a pIC50 value of 9.28-5.15. The compds. I are essentially non-toxic at therapeutically useful doses; thus no adverse effects were observed when compds. of the invention were administered to rats at a dose of 100 mg/kg. Although no specific therapeutic applications are claimed, because of the inhibition by I of Msk-1, I should be useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions, e.g. cerebral stroke; also, because of the inhibition by I of Rho kinases, I should be useful for the treatment or prophylaxis of cardiovascular and neuroinflammatory diseases. More than 300 example prepns. and/or characterization data for I are included. For example, [4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine was prepared in 4 steps (88, 94, 37 and 43 % yields, resp.) starting from 4-methoxy-3-nitropyridine hydrochloride and ethylamine and involving intermediates ethyl(3-nitropyridin-4-yl)amine, N'-ethylpyridine-3,4-diamine and (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile.

MSTR 1



G1 = 40-2 39-3



G9 = 86



G10 = pyrrolidino
G16 = Ph (opt. substd.)
G17 = N
G18 = O
G4 +G5 = 55-1 56-3



Patent location: claim 1
Note: and physiologically acceptable salts and/or N-oxides
Note: also incorporates claim 19
Note: substitution is restricted

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 131:116251 MARPAT
TITLE: Preparation of purine derivatives as adenosine A2 receptor antagonists for the treatment of diabetes
INVENTOR(S): Asano, Osamu; Harada, Hitoshi; Hoshino, Yorihisa; Yoshikawa, Seiji; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Nagata, Kaya; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935147	A1	19990715	WO 1998-JP5870	19981224
W: AU, BR, CA, CN, HU, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11263789	A2	19990928	JP 1998-363938	19981222
CA 2315736	AA	19990715	CA 1998-2315736	19981224
AU 9916885	A1	19990726	AU 1999-16885	19981224
EP 1054012	A1	20001122	EP 1998-961528	19981224
EP 1054012	B1	20030611		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
EP 1300147	A1	20030409	EP 2002-29118	19981224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 242775	E	20030615	AT 1998-961528	19981224
US 6579868	B1	20030617	US 2000-582840	20000705
PRIORITY APPLN. INFO.:			JP 1998-526	19980105
			EP 1998-961528	19981224
			WO 1998-JP5870	19981224

GI



I



II

AB The title compds. I [R1 = (un)substituted aromatic ring (which may contain heteroatom), etc.; W = CH2CH2, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, (un)substituted cycloalkyl, etc.; R4 = H, (un)substituted alkyl, heteroaryl, etc.; a proviso is given] are prepared In an in vitro test for A2a receptor antagonism, the title compound II showed the Ki value of 0.002 μM.

MSTR 1



G1 = 11



G2 = CH2CH2
G17 = OEt
G19 = 64



G21 = phenylene
Derivative: and pharmaceutically acceptable salts or hydrates
Patent location: claim 1
Note: substitution is restricted

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 126:212372 MARPAT
TITLE: Preparation of oxetanyl purines and pyrimidines nucleoside analogs as virucides
INVENTOR(S): Norbeck, Daniel W.; Plattner, Jacob J.; Rosen, Terry J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 615,138, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5597824	A	19970128	US 1992-904407	19920625
US 5420276	A	19950530	US 1993-163217	19931207
PRIORITY APPLN. INFO.:			US 1987-116605	19871103
			US 1989-453520	19891220
			US 1990-574617	19900824
			US 1990-615138	19901123
			US 1992-904407	19920625

GI



I

AB Title nucleosides I, wherein B is a purin-9-yl group or a heterocyclic isostere of a purin-9-yl group; or a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; A is -CH- or A-G taken together is -C(O)-, -C(CH2)-, -C(OH)(CH2OH)-, or epoxy, and G and D are functional groups, were prepared as virucides. Thus, 1-([2'R,3'R,4'S]-3',4'-bis(hydroxymethyl)-2'-oxetanyl)cytosine was prepared and tested for its antiviral activity against Varicella-zoster virus (MIC50 = 0,07 μg/mL).

MSTR 2



G1 = 106



G7 = CH2
G13 = aziridino
G19 = aziridino
Derivative: or pharmaceutically acceptable salts or esters
Patent location: disclosure

L8 ANSWER 7 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 115:183808 MARPAT
TITLE: Preparation of oxetanyl purines and pyrimidines as antiviral agents
INVENTOR(S): Norbeck, Daniel W.; Rosen, Terry J.; Plattner, Jacob J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 433898	A2	19910626	EP 1990-124125	19901213
EP 433898	A3	19920122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2032422	AA	19910621	CA 1990-2032422	19901217
JP 06192255	A2	19940712	JP 1990-419279	19901220
PRIORITY APPLN. INFO.:			US 1989-453520	19891220
			US 1990-574617	19900824
			US 1990-615138	19901123

GI



AB Title compds. I [B = pyrimidin-1-yl or isostere, Q; D = H, C1-10 alkyl, CH2OH, CH2OR1, CH2OCO2, etc.; R1 = C1-6 alkyl; R2 = C1-10 alkyl; A = CH; G = H, C1-10 alkyl, OH, alkoxy, NH2, alkylamino, SH, N3,CH2OH, etc., or AG = CO, C:CH2, C(OH)(CH2OH), Q1; D and G both ≠ H or C1-10 alkyl; V = O, S; R3 = OH, SH, alkoxy, thioalkoxy, halo etc.; T = H, C1-10 alkyl, etc.], were prepared Thus, 5'-O-(tert-butyldimethylsilyl)-3'-diazo-2',3'-dideoxy-2'-oxocytidine (preparation from 4-N-acetylcytidine given) in MeOH was photolyzed with a 450 W Hanovia lamp to give the corresponding 4'-silyloxy-3'-methoxycarbonyl-2'-oxetanylcytosine derivative which was reduced by NaBH4 to the 3'-hydroxymethyl analog. This was deprotected by BuNH3BF4 to give 1-([2'R,3'R,4'S]-3',4'-bis(hydroxymethyl-2'-oxetanyl)cytosine (II). II had ID50) of 0.8 and 1.0 μg/mL against HSV-1 and HSV-2, resp.

MSTR 2A



G1 = 179



G4 = (1-5) CH2
G15 = 186



G20 = 204



G30 = 292

Patent location: claim 9

MSTR 3A



G1 = 179



G4 = (1-5) CH2
G15 = 186



G20 = 204



G30 = 292



Patent location: claim 9

MSTR 4A



G1 = 176



G2 = 231

G4 = (1-5) CH2
G8 = 243



G10 = 241



G25 = 99



Derivative: or pharmaceutically acceptable salts or esters
Patent location: disclosure

L8 ANSWER 8 OF 8 MARPAT COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 110:144874 MARPAT
TITLE: Silver halide photographic material having silver iodide- and an aza-indene-containing underlayer to reduce cross-over effect
INVENTOR(S): Kawasaki, Mikio; Honda, Bon
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63199347	A2	19880817	JP 1987-31976	19870214
PRIORITY APPLN. INFO.:			JP 1987-31976	19870214

AB The claimed photog. material having light-sensitive Ag halide emulsion layers on both sides of the support is provided, between the support and ≥1 of the emulsion layer, with a light-insensitive Ag halide emulsion layer containing AgI-containing mixed crystal grains and an aza-indene compound It reduces cross-over light through the support and increases image sharpness, therefore, it is suitably used for medical radiog. diagnosis. Suitable aza-indenes are properly substituted tetraza-indenes, pentaza-indenes and triaza-indenes. Thus, (1) a substantially light-insensitive Ag(Br,I) emulsion layer (AgI 3 mol%, average size 0.18 μm) containing 1 g/mol Ag of 7-hydroxy-5-methyl-1,3,4,7'-tetraza-indene, (2) a light-sensitive Ag(Br,I) emulsion layer (AgI 2 mol%, average grain size 1.05 μm) and (3) a protective layer consisting of poly(Me methacrylate) particles, and gelatin were coated on a film support in this order. The same layer configuration was provided on the other side of the support to make a medical x-ray film.

MSTR 5



G2 = OBu-i
G3 = Ph
G4 = Ph
Patent location: disclosure